ClinicalTrials.gg
Not yet recruitingNCT07862023Updated Oct 7, 2026

Trachphone vs Warm Air Humidification for Acute Trache Patients on ICU

An observational study in Tracheostomy, Ventilated Patients and Critical Care, sponsored by Tameside General Hospital. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Tameside General Hospital · Observational

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Study summary

A tracheostomy is a surgical opening made in the windpipe (trachea) through the neck to help a person breathe. A tube is placed in the opening to keep it open. As a result, the air reaching the lungs can be cooler, drier and less well filtered. This can lead to thicker mucus, coughing, difficulty clearing secretions, and an increased risk of chest infections or breathing problems caused by mucus blockages. To help replace some of the moisture normally provided by the nose and throat, humidification is often used. Different methods of humidification are used in clinical practice, although approaches may vary between healthcare centres.

Although Heat and Moisture Exchangers (HMEs) have been available for many years for people with a tracheostomy who breathe independently, their use remains limited and varies across healthcare settings. Existing research suggests that HMEs are generally well tolerated and may help keep airway secretions thinner and easier to clear, however the evidence available is limited and further research is needed for a better understanding of the clinical benefits and limitations.

The purpose of this study is to compare two humidification methods used for tracheostomy patients receiving ventilator support in critical care: the TrachPhone, a single use Heat and Moisture Exchanger (HME) device and warm air ventilation humidification. The investigators want to understand whether either method offers advantages in secretion management, patient safety, comfort, and clinical outcomes.

02

Conditions studied

  • Tracheostomy
  • Ventilated Patients
  • Critical Care
03

In context

Lead sponsor

Tameside General Hospital is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The investigators are inviting patients aged 18 years or older, who have been admitted to the critical care unit at Tameside Hospital and have undergone a tracheostomy, to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be aged 18 years or older
  • Have undergone acute tracheostomy
  • Be admitted to Critical Care
  • Be mechanically ventilated
  • Be clinically suitable for TrachPhone™
  • Provide or have consultee agreement obtained
  • Staff that have cared for an eligible participant will be invited to participate

Exclusion criteria

Exclusion Criteria:

  • Are under 18 years of age
  • Have a clinical to TrachPhone™
  • Are receiving end-of-life care
  • Are considered unsuitable by the treating consultant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. feasibility and tolerability of TrachPhone

    The primary outcome measure will be the feasibility and tolerability of TrachPhone™ when used as intended by both patients and staff. This will be a non-validated questionnaire using a satisfaction scale, ranging from very easy to very difficult, strongly agree to strongly disagree etc.

    Time frame: from enrollment to discharge or up to 30 days

Secondary outcomes

  1. Critical care length of stay

    Number of days occupying a critical care bed

    Time frame: from enrollment to discharge, or up to 30 days

  2. Patient mobility

    Time from tracheostomy insertion to first mobilisation out of bed, Mobilisation milestones

    Time frame: Time from tracheostomy insertion to first mobilisation out of bed, assessed up to 30 days

  3. Reported quality of life

    Staff and Patient Questionnaires completed on discharge from critical care

    Time frame: on discharge, or up to 30 days

  4. Patient communication ability

    Ability to communicate wants and needs, Clinical observations, Patient questionnaire response, Staff questionnaire response

    Time frame: from enrollment to discharge, or up to 30 days

07

Study locations

1 site
  • Tameside and Glossop Integrated Care NHS Foundation Trust
    Ashton-under-Lyne, OL6 9RW, United Kingdom
    • Rebecca Roberts · Contactrd@tgh.nhs.uk · 01619224451
    • Helen Evans · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — individual participant data will not be shared outside the Trust

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Aug 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 7, 2026
StartEst.
Oct 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862023
Lead sponsor
Tameside General Hospital
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion